차세대 암 진단 시장 규모, 점유율, 성장 분석 : 제품 및 서비스별, 기술별, 암종별, 용도별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Next Generation Cancer Diagnostics Market size was valued at USD 18.84 Billion in 2024 and is poised to grow from USD 22.33 Billion in 2025 to USD 86.81 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The market for next-generation cancer diagnostics is experiencing a transformative shift towards rapid point-of-care testing, driven by the commercialization of innovative diagnostic devices, kits, and reagents. This transition is anticipated to elevate market growth, particularly with the rise of companion diagnostics, which are becoming essential in delivering advanced, personalized genomic medicine. The increasing global incidence of various cancers underscores the urgency for sophisticated diagnostic tools that facilitate early detection and subsequently improve treatment outcomes. As new biomarkers are continually developed, the accuracy and cost-effectiveness of cancer diagnostics enhance. The focus on minimally invasive techniques further emphasizes the critical role of early detection in achieving favorable patient outcomes, addressing significant healthcare challenges associated with rising cancer mortality rates.

Top-down and bottom-up approaches were used to estimate and validate the size of the Next Generation Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Next Generation Cancer Diagnostics Market Segments Analysis

Global Next Generation Cancer Diagnostics Market is segmented by Product and Services, Technology, Cancer Type, Application, End Use and region. Based on Product and Services, the market is segmented into Products and Services. Based on Technology, the market is segmented into Next-generation sequencing (NGS), Polymerase chain reaction (PCR), DNA microarrays, Multiplexing and Other technologies. Based on Cancer Type, the market is segmented into Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Cervical cancer, Liver cancer and Other cancer types. Based on Application, the market is segmented into Screening and early detection, Prognostics and monitoring, Therapy selection, Recurrence monitoring and Other applications. Based on End Use, the market is segmented into Hospitals & clinics, Diagnostic laboratories, Academic & research institutions and Other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Next Generation Cancer Diagnostics Market

The increasing demand for personalized medicine significantly contributes to the expansion of the next generation cancer diagnostics market. This approach focuses on customizing treatments to suit individual patients, taking into account their unique genetic makeup and other specific features. Advanced diagnostic tools in this sector play a crucial role by identifying patients who are most likely to respond favorably to targeted therapies. As more healthcare professionals recognize the advantages of these tailor-made treatment strategies, the reliance on innovative diagnostic solutions intensifies, thereby propelling market growth and enhancing patient outcomes in cancer care.

Restraints in the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market faces significant challenges due to unclear reimbursement policies, which hinder the adoption of innovative technologies. This uncertainty creates obstacles for healthcare providers and patients, as justifying the costs associated with advanced diagnostic tests becomes complicated. Variability in reimbursement policies across different countries, regions, and healthcare systems further exacerbates the issue. Many of these policies remain underdeveloped, leading to a lack of consensus on appropriate reimbursement methods for these cutting-edge diagnostics. Consequently, the financial implications can deter healthcare providers from fully integrating these valuable tools into clinical practice, limiting their potential impact on patient care.

Market Trends of the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market is witnessing a significant shift towards liquid biopsy tests, which are increasingly recognized for their potential to revolutionize cancer diagnosis and monitoring. By utilizing non-invasive methods to analyze bodily fluids such as blood and urine, these tests offer a safer, more cost-effective alternative to traditional tissue biopsies. Their ability to provide timely and precise insights into cancer presence and progression is driving their rapid adoption among healthcare providers and patients alike. Consequently, this trend has attracted substantial investments from companies aiming to innovate and enhance the efficacy of liquid biopsy technologies, further propelling market growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Next Generation Cancer Diagnostics Market Size by Product and Services & CAGR (2026-2033)

• Market Overview
• Products
  • Instruments
  • Kits & consumables
• Services

Global Next Generation Cancer Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Next-generation sequencing (NGS)
• Polymerase chain reaction (PCR)
• DNA microarrays
• Multiplexing
• Other technologies

Global Next Generation Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Breast cancer
• Lung cancer
• Colorectal cancer
• Prostate cancer
• Cervical cancer
• Liver cancer
• Other cancer types

Global Next Generation Cancer Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Screening and early detection
• Prognostics and monitoring
• Therapy selection
• Recurrence monitoring
• Other applications

Global Next Generation Cancer Diagnostics Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Hospitals & clinics
• Diagnostic laboratories
• Academic & research institutions
• Other end users

Global Next Generation Cancer Diagnostics Market Size & CAGR (2026-2033)

• North America (Product and Services, Technology, Cancer Type, Application, End Use)
  • US
  • Canada
• Europe (Product and Services, Technology, Cancer Type, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product and Services, Technology, Cancer Type, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product and Services, Technology, Cancer Type, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product and Services, Technology, Cancer Type, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Germany/Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations